{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T20:05:25Z","timestamp":1784923525670,"version":"3.55.0"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Central Funds Guiding Local Science and Technology Development","award":["2025ZY01093"],"award-info":[{"award-number":["2025ZY01093"]}]},{"DOI":"10.13039\/501100017594","name":"Zhejiang Provincial Medicine and Health Science Foundation","doi-asserted-by":"publisher","award":["2023KY174"],"award-info":[{"award-number":["2023KY174"]}],"id":[{"id":"10.13039\/501100017594","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017594","name":"Zhejiang Provincial Medicine and Health Science Foundation","doi-asserted-by":"publisher","award":["2025KY1061"],"award-info":[{"award-number":["2025KY1061"]}],"id":[{"id":"10.13039\/501100017594","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82003838"],"award-info":[{"award-number":["82003838"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004731","name":"Zhejiang Province Natural Science Foundation of China","doi-asserted-by":"publisher","award":["LY22H310006"],"award-info":[{"award-number":["LY22H310006"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Construction Fund of Key Medical Disciplines of Hangzhou","award":["2025HZZD02"],"award-info":[{"award-number":["2025HZZD02"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Pregnant women are at increased risk of severe coronavirus disease 2019 with potential adverse consequences for maternal and fetal health. Although remdesivir (RDV), molnupiravir and azvudine are RNA-dependent RNA polymerase (RdRp) inhibitors of SARS-CoV-2, their placental transport characteristics are unclear. This study aimed to compare the placental permeability and transport mechanisms of these antiviral drugs using placental cell models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A cost-effective LC-MS\/MS method quantified these drugs and their metabolites. Drug accumulation in placental cell models was compared, and drug permeability was assessed using BeWo Transwell transport assay. Transporter inhibitors, siRNA knockdown and transporter-overexpression cell models were used to investigate the transmembrane transport mechanisms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>RDV, GS-441524 and EIDD-1931 accumulated more in BeWo cells at 37\u00b0C than at 4\u00b0C, indicating carrier-mediated uptake. RDV and GS-441524 exhibited lower permeability, whereas EIDD-1931 and azvudine exhibited higher permeability in BeWo cells. RDV was a potential substrate of equilibrative nucleoside transporter (ENT) 1\/2 and concentrative nucleoside transporter (CNT) 3; GS-441524 of ENT1\/2, CNT2\/3 and organic anion transporter (OAT) 4; and EIDD-1931 of ENT1\/2 and OAT4. Breast cancer resistance protein (BCRP) was implicated in efflux of all four compounds in BeWo cells, whereas P-glycoprotein (P-gp) was involved in efflux of RDV and GS-441524.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>RDV and GS-441524 displayed low placental permeability in BeWo cells, whereas EIDD-1931 and azvudine displayed high permeability. Multiple ENTs, CNTs, OAT4, P-gp and BCRP might be involved in placental transport of RDV, GS-441524, EIDD-1931 and azvudine. These findings offer new insights into the placental transport of RdRp inhibitors during pregnancy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkag257","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T11:50:57Z","timestamp":1784116257000},"source":"Crossref","is-referenced-by-count":0,"title":["Comparison of the permeability of RdRp inhibitors, remdesivir, molnupiravir and azvudine, in placental barrier cell models and exploration of their transport mechanisms"],"prefix":"10.1093","volume":"81","author":[{"given":"Qian","family":"Shen","sequence":"first","affiliation":[{"name":"Zhejiang Institute for Food and Drug Control, Zhejiang Key Laboratory of Biopharmaceutical Contact Materials , Hangzhou 310052 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People\u2019s Hospital, School of Medicine, Westlake University , Hangzhou 310006 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuixian","family":"Zhang","sequence":"additional","affiliation":[{"name":"Obstetrics and Gynecology, Affiliated Hangzhou First People\u2019s Hospital, School of Medicine, Westlake University , Hangzhou 310006 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kundan","family":"Zhu","sequence":"additional","affiliation":[{"name":"Zhejiang Institute for Food and Drug Control, Zhejiang Key Laboratory of Biopharmaceutical Contact Materials , Hangzhou 310052 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyang","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, West China Hospital, Sichuan University , Chengdu 610041 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Liu","sequence":"additional","affiliation":[{"name":"Shanghai AB Sciex Analytical Instrument Trading Co., Ltd. , Shanghai 200050 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Obstetrics and Gynecology, Affiliated Hangzhou First People\u2019s Hospital, School of Medicine, Westlake University , Hangzhou 310006 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6806-388X","authenticated-orcid":false,"given":"Mengru","family":"Bai","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People\u2019s Hospital, School of Medicine, Westlake University Department of , Hangzhou 310006 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"2026072415101143300_dkag257-B1","doi-asserted-by":"publisher","DOI":"10.1111\/aji.13317","article-title":"Is pregnancy an immunological contributor to severe or controlled COVID-19 disease?","volume":"84","author":"Hanna","year":"2020","journal-title":"Am J Reprod Immunol"},{"key":"2026072415101143300_dkag257-B2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3320","article-title":"Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis","volume":"370","author":"Allotey","year":"2020","journal-title":"BMJ"},{"key":"2026072415101143300_dkag257-B3","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1177\/1093526620925569","article-title":"Placental pathology in COVID-19 positive mothers: preliminary findings","volume":"23","author":"Baergen","year":"2020","journal-title":"Pediatr Dev Pathol"},{"key":"2026072415101143300_dkag257-B4","doi-asserted-by":"publisher","first-page":"522.e1","DOI":"10.1016\/j.ajog.2021.05.016","article-title":"Maternal and perinatal outcomes of pregnant women with SARS-CoV-2 infection at the time of birth in England: national cohort study","volume":"225","author":"Gurol-Urganci","year":"2021","journal-title":"Am J Obstet Gynecol"},{"key":"2026072415101143300_dkag257-B5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0268591","article-title":"Placental vascular remodeling in pregnant women with COVID-19","volume":"17","author":"Gychka","year":"2022","journal-title":"PLoS One"},{"key":"2026072415101143300_dkag257-B6","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1093\/ajcp\/aqaa089","article-title":"Placental pathology in COVID-19","volume":"154","author":"Shanes","year":"2020","journal-title":"Am J Clin Pathol"},{"key":"2026072415101143300_dkag257-B7","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1001\/jamapediatrics.2021.1050","article-title":"Maternal and neonatal morbidity and mortality among pregnant women with and without COVID-19 infection: the INTERCOVID multinational cohort study","volume":"175","author":"Villar","year":"2021","journal-title":"JAMA Pediatr"},{"key":"2026072415101143300_dkag257-B8","doi-asserted-by":"publisher","first-page":"3131","DOI":"10.1038\/s41598-023-29517-9","article-title":"Expanded profiling of remdesivir as a broad-spectrum antiviral and low potential for interaction with other medications in vitro","volume":"13","author":"Radoshitzky","year":"2023","journal-title":"Sci Rep"},{"key":"2026072415101143300_dkag257-B9","author":"U.S. Food and Drug Administration"},{"key":"2026072415101143300_dkag257-B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104095","article-title":"Biotransformation and transplacental transfer of the anti-viral remdesivir and predominant metabolite, GS-441524 in pregnant rats","volume":"81","author":"Yang","year":"2022","journal-title":"EBioMedicine"},{"key":"2026072415101143300_dkag257-B11","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.1144","article-title":"Transplacental transfer of remdesivir and GS-441524: an ex vivo perfusion study","volume":"6","author":"Louchet","year":"2023","journal-title":"Health Sci Rep"},{"key":"2026072415101143300_dkag257-B12","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.70488","article-title":"In Vitro synergistic antiviral effects of \u03b2-D-N4-hydroxycytidine and teriflunomide in combination against a broad range of RNA viruses","volume":"97","author":"Sirihongthong","year":"2025","journal-title":"J Med Virol"},{"key":"2026072415101143300_dkag257-B13","author":"U.S. Food and Drug Administration"},{"key":"2026072415101143300_dkag257-B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104748","article-title":"Transfer and biotransformation of the COVID-19 prodrug molnupiravir and its metabolite beta-D-N4-hydroxycytidine across the blood-placenta barrier","volume":"95","author":"Chang","year":"2023","journal-title":"EBioMedicine"},{"key":"2026072415101143300_dkag257-B15","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1093\/jac\/dkaf302","article-title":"Placental transfer of medications to treat COVID-19, molnupiravir, favipiravir and nirmatrelvir\/ritonavir, in the ex vivo human cotyledon model","volume":"80","author":"Labaye","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"2026072415101143300_dkag257-B16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0105617","article-title":"Azvudine, A novel nucleoside reverse transcriptase inhibitor showed good drug combination features and better inhibition on drug-resistant strains than lamivudine In Vitro","volume":"9","author":"Wang","year":"2014","journal-title":"PLoS One"},{"key":"2026072415101143300_dkag257-B17","author":"National Medical Products Administration"},{"key":"2026072415101143300_dkag257-B18","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.clpt.2005.04.014","article-title":"Functional role of P-glycoprotein in the human blood-placental barrier","volume":"78","author":"Molsa","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"2026072415101143300_dkag257-B19","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.placenta.2014.11.001","article-title":"Drug transporter expression during in vitro differentiation of first-trimester and term human villous trophoblasts","volume":"36","author":"Berveiller","year":"2015","journal-title":"Placenta"},{"key":"2026072415101143300_dkag257-B20","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1124\/dmd.121.000685","article-title":"Bilirubin reduces the uptake of estrogen precursors and the followed synthesis of estradiol in human placental syncytiotrophoblasts via inhibition and downregulation of organic anion transporter 4","volume":"50","author":"Zhang","year":"2022","journal-title":"Drug Metab Dispos"},{"key":"2026072415101143300_dkag257-B21","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1124\/mol.111.071837","article-title":"Expression and distribution of nucleoside transporter proteins in the human syncytiotrophoblast","volume":"80","author":"Errasti-Murugarren","year":"2011","journal-title":"Mol Pharmacol"},{"key":"2026072415101143300_dkag257-B22","doi-asserted-by":"publisher","first-page":"R1809","DOI":"10.1152\/ajpregu.00293.2007","article-title":"In situ hybridization and immunolocalization of concentrative and equilibrative nucleoside transporters in the human intestine, liver, kidneys, and placenta","volume":"293","author":"Govindarajan","year":"2007","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"2026072415101143300_dkag257-B23","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1517\/17425255.2015.1005073","article-title":"Regulation of drug transporter expression and function in the placenta","volume":"11","author":"Staud","year":"2015","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2026072415101143300_dkag257-B24","doi-asserted-by":"publisher","first-page":"2732","DOI":"10.1021\/acs.molpharmaceut.8b00238","article-title":"Expression of concentrative nucleoside transporters (SLC28A) in the human placenta: effects of gestation age and prototype differentiation-affecting agents","volume":"15","author":"Jiraskova","year":"2018","journal-title":"Mol Pharm"},{"key":"2026072415101143300_dkag257-B25","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00199-19","article-title":"Multiple drug transporters contribute to the placental transfer of emtricitabine","volume":"63","author":"Zeng","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2026072415101143300_dkag257-B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2024.116268","article-title":"Evaluation of transport mechanisms of methotrexate in human choriocarcinoma cell lines by LC-MS\/MS","volume":"247","author":"Bai","year":"2024","journal-title":"J Pharm Biomed Anal"},{"key":"2026072415101143300_dkag257-B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhazmat.2023.133205","article-title":"Transplacental transport of per- and polyfluoroalkyl substances (PFAS): mechanism exploration via BeWo cell monolayer model","volume":"466","author":"Chen","year":"2024","journal-title":"J Hazard Mater"},{"key":"2026072415101143300_dkag257-B28","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1123194","article-title":"Transplacental passage of hyperforin, hypericin, and valerenic acid","volume":"14","author":"Spiess","year":"2023","journal-title":"Front Pharmacol"},{"key":"2026072415101143300_dkag257-B29","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1385\/1-59259-989-3:225","article-title":"In vitro models for studying trophoblast transcellular transport","volume":"122","author":"Bode","year":"2006","journal-title":"Methods Mol Med"},{"key":"2026072415101143300_dkag257-B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116177","article-title":"Safety assessment of the SGLT2 inhibitors empagliflozin, dapagliflozin and canagliflozin during pregnancy: an ex vivo human placenta perfusion and in vitro study","volume":"171","author":"Kuoni","year":"2024","journal-title":"Biomed Pharmacother"},{"key":"2026072415101143300_dkag257-B31","author":"Food and Drug Administration"},{"key":"2026072415101143300_dkag257-B32","doi-asserted-by":"publisher","first-page":"E390","DOI":"10.1152\/ajpendo.00257.2002","article-title":"Characterization and identification of steroid sulfate transporters of human placenta","volume":"284","author":"Ugele","year":"2003","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2026072415101143300_dkag257-B33","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1124\/molpharm.121.000333","article-title":"Remdesivir and EIDD-1931 interact with human equilibrative nucleoside transporters 1 and 2: implications for reaching SARS-CoV-2 viral sanctuary sites","volume":"100","author":"Miller","year":"2021","journal-title":"Mol Pharmacol"},{"key":"2026072415101143300_dkag257-B34","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/s41589-024-01559-8","article-title":"Antiviral drug recognition and elevator-type transport motions of CNT3","volume":"20","author":"Wright","year":"2024","journal-title":"Nat Chem Biol"},{"key":"2026072415101143300_dkag257-B35","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ejps.2017.05.009","article-title":"Intestinal absorption mechanisms of 2'-deoxy-2'-beta-fluoro-4'-azidocytidine, a cytidine analog for AIDS treatment, and its interaction with P-glycoprotein, multidrug resistance-associated protein 2 and breast cancer resistance protein","volume":"105","author":"Liu","year":"2017","journal-title":"Eur J Pharm Sci"},{"key":"2026072415101143300_dkag257-B36","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.918083","article-title":"Preclinical pharmacokinetics and In Vitro properties of GS-441524, a potential oral drug candidate for COVID-19 treatment","volume":"13","author":"Wang","year":"2022","journal-title":"Front Pharmacol"},{"key":"2026072415101143300_dkag257-B37","doi-asserted-by":"publisher","first-page":"e3996","DOI":"10.1093\/cid\/ciaa1466","article-title":"Compassionate use of remdesivir in pregnant women with severe coronavirus disease 2019","volume":"73","author":"Burwick","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2026072415101143300_dkag257-B38","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1097\/AOG.0000000000004734","article-title":"Early administration of remdesivir and intensive care unit admission in hospitalized pregnant individuals with coronavirus disease 2019 (COVID-19)","volume":"139","author":"Eid","year":"2022","journal-title":"Obstet Gynecol"},{"key":"2026072415101143300_dkag257-B39","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1093\/jac\/dkab311","article-title":"A review of remdesivir for COVID-19 in pregnancy and lactation","volume":"77","author":"Jorgensen","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2026072415101143300_dkag257-B40","doi-asserted-by":"publisher","first-page":"4114","DOI":"10.1002\/jmv.26986","article-title":"Remdesivir for the treatment of COVID-19 in pregnancy","volume":"93","author":"Lampejo","year":"2021","journal-title":"J Med Virol"},{"key":"2026072415101143300_dkag257-B41","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1093\/infdis\/jiae298","article-title":"Pharmacokinetics and safety of remdesivir in pregnant and nonpregnant women with COVID-19: results from IMPAACT 2032","volume":"230","author":"Brooks","year":"2024","journal-title":"J Infect Dis"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/8\/dkag257\/69969162\/dkag257.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/8\/dkag257\/69969162\/dkag257.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T19:10:18Z","timestamp":1784920218000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkag257\/8741629"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":41,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,7,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkag257","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,7,2]]},"article-number":"dkag257"}}